Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Cancer Res. 2008 Nov 1;68(21):8899–8907. doi: 10.1158/0008-5472.CAN-08-2568

Figure 6. Cdc42 controls the survival and proliferation of ALCL cells in vitro and the growth rate of ALCL cells in vivo.

Figure 6

A, DNA content was analyzed after propidium-iodide staining on TS cells transduced with inducible sh-Cdc42 or control sequences after 4 days of induction with 1 μg/ml of doxycycline. Data are from one of four independent experiments. B, ALK positive (TS and SU-DHL1) and ALK negative (MAC-1 and Jurkat) cell lines were treated for 6 hours with 10 μM Cdc42 inhibitor Secramine A in combination with the indicated concentrations of the selective ALK kinase inhibitor CEP-14083. Percentages of apoptotic cells were measured by TMRM staining. C, 107 TS cells transduced with either one of the two sh-Cdc42 sequences or with the control sequence were injected subcutaneously into SCID-Beige immunocompromised mice. Mice were fed with water containing 1mg/ml doxycycline for the entire time of the experiments. Tumor growth was measured over time. Data are represented as mean +/− SD. Data are from at least six mice for each group. D, 107 TS cells transduced with one sh-Cdc42 sequence or with a control sequence were injected s.c. into SCID-Beige immunocompromised mice. When tumors reached the size of 20 mm in maximum diameter, we started to treat the mice with water containing 1mg/ml doxycycline. Tumor growth was then measured over time. Mice were sacrificed for ethical reasons when tumors reached the diameter of 30 mm. Data are represented as mean +/− SD. Data are from at least three mice for each group.